35 results about "Macular oedema" patented technology

Diabetes is a disease characterized by high levels of blood glucose. It is important to keep diabetes under control to avoid short- and long-term complications. Diabetes can affect vision due to the alterations it produces in the blood vessels of the retina. This is known as Diabetic Retinopathy (DR), which is one of the leading causes of impaired vision in developed countries. One of the complications of diabetic retinopathy is Diabetic Macular Edema (DME), which is the leading cause of vision loss in diabetic patients and can appear at any stage of diabetic retinopathy. This consists of the gradual accumulation of fluid in the macula, the most important area of the retina. The determination of diabetic macular oedema is very important for the retina. The determination of diabetic macular oedema is very important for adequate treatment of this condition. A variety of technological options are used for detecting diabetic retinopathy, although only the most sophisticated detect macular oedema, a complication that appears as a consequence of diabetic retinopathy and is one of the leading causes of blindness. The invention describes a portable system for detecting diabetic macular oedema by capturing a fundus image using a portable ophthalmoscope; said image is sent via wired or wireless means to an embedded system that has an algorithm based on artificial intelligence, which extracts information from the image and processes same to identify the presence of the condition being studied.

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention provides extracellular vesicle proteins sPTPRG and Vincin of a biomarker for detecting retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing, the difference of the expression quantity of the extracellular vesicle proteins in aqueous humor of a patient is analyzed, the protein with remarkable expression difference is screened out, the protein can be used as the biomarker for RVO-ME treatment, and the application of the biomarker for detecting the anti-VEGF treatment typing of the retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing of the RVO-ME anti-VEGF treatment typing is facilitated. Important guidance is provided for personalized treatment of RVO-ME, and the method has a wide clinical application prospect.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The invention is concerned with a method of predicting response to an IL-6 angatonist such as anti-IL-6 antibody by determing the concentration of IL-6 in human aqueous humor. The invention is also concerned with an IL-6 angatonist for use in treatment of uveitis or uveitic macular edema.

Pharmaceutical compositions comprising adeno-associated virus (AAV) and their use in treating diabetic macular edema are provided herein. In some aspects, treatment methods encompass co-administration of one or more corticosteroids and / or supplemental administrations of aflibercept protein.

The present invention relates to a method for the production of an ocular implant, wherein dexamethasone — commonly employed in the treatment of macular edema resulting from retinal vein occlusion (RVO) and diabetic macular edema (DME) — is encapsulated within a nanofibrous matrix fabricated via electrospinning, and said nanofibers are subsequently coated onto a contact lens surface.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The present invention belongs to the field of tumor immunotherapy, and relates to a humanized anti-VEGF antibody Fab fragment. The present invention discloses nucleic acid sequences (including heavy / light chain variable regions) encoding said antibody fragment, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The anti-VEGF antibody Fab fragments disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2, and also neutralize the proliferative effect of VEGF on HUVEC cells. Compared to the full-length antibody, antibodies in the form of Fab fragments have stronger penetrability and less toxic in terms of gastrointestinal perforation, hypertension and hemorrhage and do not stimulate the complement cascade reaction, thus reducing the risk of endophthalmitis and autoimmune inflammatory reactions. Thus it could be used in clinical treatment of ocular diseases characterized by choroidal neovascularization, including but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV).

The invention relates to a traditional Chinese medicine composition for treating macular edema, which is prepared from the following traditional Chinese medicines in parts by weight: 5-35 parts of astragalus mongholicus, 1-30 parts of radix rehmanniae recen, 1-30 parts of radix angelicae, 1-30 parts of rhizoma atractylodis macrocephalae and 1-30 parts of rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-30 parts of poria cocos, 1-20 parts of radix achyranthis bidentatae, 1-20 parts of moutan bark, 1-20 parts of fructus gardeniae, 1-20 parts of radix salviae miltiorrhizae, 1-20 parts of radix scrophulariae, 1-20 parts of radix ophiopogonis, 1-20 parts of radix paeoniae alba, 1-15 parts of radix curcumae, 1-10 parts of radix notoginseng and 1-10 parts of lotus leaves. The traditional Chinese medicine composition can effectively relieve macular edema after macular anterior membrane vitrectomy, has positive effects on improving the inflammatory state, microcirculation and metabolic function of a macular region of a patient, and is safe in clinical use.

An ophthalmic preparation for treating macular edema, optic neuritis and non-infectious endophthalmitis contains an active ingredient for treating eye diseases and an ophthalmic preparation carrier or auxiliary material. The active ingredient for treating eye diseases is a glucocorticoid medicine and / or a non-steroidal medicine. The ophthalmic preparation carrier or auxiliary material contains the following ingredients: a surfactant, an ionic polymer and a solvent, or the ophthalmic preparation carrier or auxiliary material contains the following ingredients: povidone with low polymerization degree, povidone with moderate polymerization degree and a solvent. The ophthalmic preparation can carry (wrap) the glucocorticoid and / or the non-steroidal medicines to penetrate through the anterior segment of eyes and be conveyed to the posterior segment of eyes to treat the macular edema, the optic neuritis and the non-infectious endophthalmitis in an eye drop administration mode, and the ophthalmic preparation has extremely excellent clinical use value and positive social significance.

To provide treatment of AMD using an AAV2 variant with aflibercept.SOLUTION: The present disclosure provides pharmaceutical compositions and methods thereof for treatment of age-related macular degeneration (AMD) in a subject by administering intravitreally a pharmaceutical composition adapted for gene therapy, comprising a vector having a nucleic acid sequence that encodes aflibercept. The present disclosure relates to pharmaceutical compositions and methods for prevention or treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) in patients with DME, retinal vein occlusion, and related eye diseases or conditions, in a primate or human subject by administering intravitreally or subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector or viral particles (e.g., rAAV) comprising a nucleic acid encoding aflibercept or a functional fragment or variant thereof.SELECTED DRAWING: None

The present invention relates to a method for predicting response to an IL-6 antagonist, such as an anti-IL-6 antibody, by determining the concentration of IL-6 in human aqueous humor. The present invention also relates to an IL-6 antagonist for use in treating uveitis or uveitic macular edema.

The present invention relates to novel methods, uses and compositions of annexin A5 protein as combination therapy with one or more anti-VEGF agents, the present invention relates to compounds, for example, for the prevention or treatment of macular edema, retinal vein occlusion and / or one or more diseases, conditions or conditions associated with and / or caused by macular edema or retinal vein occlusion, and / or other conditions suitable for treatment with anti-VEGF agents. In a preferred embodiment, the annexin A5 is administered systemically, such as intravenously.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for treating ocular diseases or conditions, including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. The compositions and methods comprise steroids and prostaglandins that exhibit anti-inflammatory activity, reduce intraocular pressure (IOP), and / or other desirable activities. Injection of the compositions in the eye provides therapeutic benefits to patients suffering from ocular conditions.

The invention provides methods, compositions, and kits containing a first therapeutic agent that is a substituted 2,3-dimethoxyquinone of Formula I, or a pharmaceutically acceptable salt thereof, for preventing the progression of diabetic retinopathy, diabetic macular edema, and / or other retinal disorders and / or other disorders.

The present disclosure relates to a method of treating diabetic macular edema in a human subject in need thereof, the method comprising (i) an induction period of topical administration of an eye drop formulation comprising 1.5% (w / v) dexamethasone to a diseased eye of the subject in a dose of 5-7 drops per day for 3, 4, 5, 6 weeks followed by (ii) a maintenance period of topical administration of an eye drop formulation comprising 1.5% (w / v) dexamethasone to a diseased eye of the subject in a dose of 5-7 drops per day. The eye drop formulation comprising 1.5% (w / v) dexamethasone is topically administered to a diseased eye of the subject at a daily dose lower than the induction period frequency (e.g., 1-3 drops).

The invention relates to the technical field of image data processing, in particular to a macular oedema dynamic change monitoring method based on an OCT (optical coherence tomography) tomographic image, which comprises the following steps: acquiring a reference OCT image, a micro-angle change OCT image and an OCTA blood flow image of an eye macular area of a patient; determining the change intensity of pixel points by using a gray value change sequence in the OCTA blood flow image sequence, and determining a macular oedema existing area in the reference OCT image based on the change intensity; performing peak detection on the gray histogram of the macular oedema existing area based on the gray features of the cyst area to obtain a cyst candidate area; and determining a cyst candidate area, and obtaining a cyst area in the reference OCT image by using a gray value sequence of pixel points in the aligned cyst candidate area. According to the method, the influence of the vessel shadow is eliminated, the segmented cyst part is more accurate and complete, and the dynamic change monitoring effect is remarkably improved.

The present invention relates to a stable liquid formulation of a fusion protein having an Fc domain of human immunoglobulin G (IgG) (in particular, a protein in which a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor and an Fc domain of human immunoglobulin G (IgG) are fused (e.g. Aflibercept)). The present invention also relates to a composition for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor and an Fc domain of IgG are fused, and a method for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor and an Fc domain of IgG are fused. The present invention can promote stabilization of physiological activity through a stable liquid formulation suitable for intravitreal injection of anti-VEGF-Fc fusion proteins including Aflibercept, and improve the therapeutic effect on various ophthalmic diseases caused by abnormal angiogenesis (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization, and wet age-related macular degeneration, etc.).

To provide dosing regimens for angiogenic eye disorders, particularly regimens that allow less frequent dosing while maintaining high levels of efficacy.SOLUTION: The present invention provides a method of treating an angiogenic eye disorder by sequentially administering multiple dosing of a VEGF antagonist to a patient. The method comprises administering to the patient multiple dosing of the VEGF antagonist at a frequency of once every 8 weeks or once every more weeks. The method is useful for treating angiogenic eye disorders such as age-related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and corneal neovascularization.SELECTED DRAWING: None

The present invention relates to heteroarylcarboxamide compounds and their pharmaceutical uses. Specifically, the present invention relates to heteroarylcarboxamide compounds represented by general formula (I), methods for producing the same, pharmaceutical compositions containing the compound, and their use as therapeutic agents, particularly as plasma kallikrein (PKa) selective inhibitors, and in the treatment and / or prevention of diseases that may benefit from plasma kallikrein inhibition, particularly for the prevention and / or treatment of diabetic macular edema (DME), age-related macular degeneration (AMD), choroidal angiogenesis, hereditary angioedema (HAE), and post-stroke cerebral edema. JPEG2026525258000208.jpg2785

The present invention is directed to methods for treating diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), wet age-related macular degeneration (AMD) and / or retinal vein occlusion (RVO) in a patient or subject in need comprising administering an effective amount of at least one anti-DME agent selected from the group consisting of desipramine, protriptyline, cyclosporin A, crisaborole, empagliflozin, nitroxolone, suprofen, sulfisoxazole, methapyrilene, phentolamine, naphazoline or a pharmaceutically acceptable salt thereof, preferably at least one agent selected from the group consisting of desipramine, nitroxolone, methapyriline, phentolamine, napthazoline and their pharmaceutically acceptable salts.

The invention provides a construction method of a retinal vein occlusion animal model, and belongs to the technical field of medicines. The method comprises the following steps of: performing eyeball surface anesthesia on an anesthetized non-human primate animal, puncturing an eyeball after disinfection to establish two sclera tunnels, respectively inserting an illumination optical fiber and an intraocular laser optical fiber into the two sclera tunnels, then injecting a photosensitizer through limb vein, immediately performing laser photocoagulation on the retinal vein under illumination of the illumination optical fiber after injection, and performing laser photocoagulation on the retinal vein under the illumination of the illumination optical fiber. And obtaining the retinal vein occlusion animal model. According to the method, the retinal vein occlusion model can be successfully constructed, secondary macular edema and vascular recanalization are carried out for a long time and can be maintained for 4-5 weeks, the manifestation sign of retinal hemorrhage after retinal vein occlusion is close to that of human beings, and the method has clinical drug responsiveness, shows the clinical research value and has good application prospects. And a good research model is provided for research in the aspects of etiology, pathology and therapeutics.

The present disclosure relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound for the treatment of ocular diseases. The ocular diseases include, but are not limited to, proliferative vitreoretinopathy, cystoid macular edema, central serous retinopathy, diabetic retinopathy, endophthalmitis, epiretinal membrane, and toxoplasmosis. The present disclosure also relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound to inhibit glial scar formation or reduce glial scar length.

The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds, and methods of using the compounds to treat or prevent one or more conditions that can benefit from the inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular edema, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.